CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 994 enrolled
Drug / intervention
S-ICD Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01085435
NCT01085435N/ACompleted

Evaluation oF Factors ImpacTing CLinical Outcome and Cost EffectiveneSS of the S-ICD (The EFFORTLESS S-ICD Registry)

Boston Scientific Corporation·observational·Posted Mar 11, 2010·Updated May 20, 2025

In Brief

An observational study evaluating S-ICD System for Tachycardia, Ventricular. Completed, enrolled 994 participants across 44 sites in 10 countries.

Detailed Summary

The EFFORTLESS ICD Registry is an observational, standard of care evaluation designed to demonstrate the early, mid and long-term clinical effectiveness the Boston Scientific S-ICD System. In addition, analysis of resource utilization and costs will be performed to document treatment costs for periods defined by Registry endpoints. Protocol 90904928 restricts enrolment to patients over 18 years of age while protocol 90904925 allows all patients to be included.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesCzechia, Denmark, France, Germany, Italy, Netherlands, New Zealand, Portugal, Spain, United Kingdom
Collaborators--

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 11, 2010
Enrollment StartFeb 2, 2011
Primary CompletionFeb 29, 2020
Study CompletionJan 1, 2024
TodayJul 2, 2026
Enrollment to primary: 9.1 yearsPosted 16.3 years ago

Interventions

S-ICD Systemdevice

The S-ICD System is an implantable technology that uses a subcutaneous pulse generator and subcutaneous electrode system to treat ventricular tachyarrhythmias. The S-ICD System consists of the pulse generator, subcutaneous electrode, the programmer and electrode insertion tool.